# OnCo record rejuv-tx-what-to-ask-for (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/rejuv-tx-what-to-ask-for/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "rejuv-tx-what-to-ask-for" ;
  schema:name "After a transplant or cell therapy: what to ask for"@en ;
  schema:alternateName "transplant survivorship checklist"@en, "questions after transplant"@en, "post-transplant follow-up checklist"@en ;
  schema:description "The things worth asking a transplant team for, in one place: who follows you up and for how long, which screens are due at which year, what immunisations you need and when, and who to ring when something changes."@en ;
  schema:url <https://onco.cc/technologies/rejuv-tx-what-to-ask-for/> ;
  schema:dateModified "2026-10-02"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Hematopoietic_stem_cell_transplantation> ;
  schema:citation <https://doi.org/10.1016/j.bbmt.2011.12.519>, <https://doi.org/10.1016/S1473-3099(18)30600-5>, <https://doi.org/10.1016/j.jinf.2022.11.005>, <https://doi.org/10.1182/blood-2008-05-158782>, <https://doi.org/10.3324/haematol.2016.150250>, <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/long-term-follow-after-administration-human-gene-therapy-products> ;
  onco:status "standard-of-care" ;
  onco:tag "rejuvenation", "survivorship", "transplant", "evidence:strong", "follow-up", "summary" ;
  onco:related <https://onco.cc/technologies/gvhd-chronic-overview/>, <https://onco.cc/technologies/gvhd-nih-consensus-criteria/>, <https://onco.cc/technologies/gvhd-organ-by-organ/>, <https://onco.cc/technologies/gvhd-lung-bronchiolitis-obliterans/>, <https://onco.cc/technologies/gvhd-prophylaxis/>, <https://onco.cc/technologies/gvhd-ruxolitinib-steroid-refractory/>, <https://onco.cc/technologies/gvhd-belumosudil-axatilimab-ibrutinib/>, <https://onco.cc/technologies/gvhd-photopheresis/>, <https://onco.cc/technologies/rejuv-tx-late-effects-overview/>, <https://onco.cc/technologies/rejuv-tx-survival-after-transplant/>, <https://onco.cc/technologies/rejuv-tx-second-cancers/>, <https://onco.cc/technologies/rejuv-tx-iron-overload/>, <https://onco.cc/technologies/rejuv-tx-bone-eyes-kidneys-lungs/>, <https://onco.cc/technologies/rejuv-tx-endocrine-and-cardiometabolic/>, <https://onco.cc/technologies/rejuv-tx-immune-reconstitution-timeline/>, <https://onco.cc/technologies/rejuv-tx-b-cell-aplasia-and-immunoglobulin/>, <https://onco.cc/technologies/rejuv-tx-infection-by-phase/>, <https://onco.cc/technologies/rejuv-tx-revaccination/>, <https://onco.cc/technologies/rejuv-tx-prolonged-cytopenias/>, <https://onco.cc/technologies/rejuv-tx-icans-and-neurocognition/>, <https://onco.cc/technologies/rejuv-tx-secondary-t-cell-malignancy/>, <https://onco.cc/technologies/rejuv-tx-gene-modified-follow-up/>, <https://onco.cc/technologies/rejuv-tx-long-term-follow-up-frameworks/>, <https://onco.cc/technologies/rejuv-tx-fertility-and-growth/>, <https://onco.cc/technologies/rejuv-tx-quality-of-life/>, <https://onco.cc/technologies/rejuv-frontier-immune-reconstitution/>, <https://onco.cc/technologies/rejuv-frontier-what-works/> ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/technologies/fertility-preservation/> ;
  onco:terms <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/gvhd/>, <https://onco.cc/terms/quality-of-life/>, <https://onco.cc/terms/secondary-malignancy/>, <https://onco.cc/terms/hypogammaglobulinaemia/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-survivorship/>, <https://onco.cc/bottlenecks/b-toxicity-qol/> .